Product
Total
Volume
200 mg/ 20 ml
Propofol-Lipuro
10 mg/ml
200 mg/ 20 ml
500 mg/ 50 ml
1000 mg/100 ml
Container
Sales
Type
Unit
Glass
5 x 20 ml
Ampoule
Single Dose
10 x 20 ml
Glass Vial
Single Dose
10 x 50 ml
Glass Vial
Single Dose
10 x 100 ml
Glass Vial
Product
Propofol-Lipuro
20 mg/ml
Total
Volume
1000 mg/50 ml
Container
Type
Single Dose
Glass Vial
Sales
Unit
10 x 50 ml
Injectable Drugs
Injectable Drugs
Lipuro-Technology
Technology & Innovation:
Propofol-Lipuro is a highly innovative product from B. Brauns
unique Lipuro-Technology, which uses MCT/LCT lipid emulsion
as the drug delivery base with excellent solubility and stability.
Clinical approval:
Since its launch in 1999, Propofol-Lipuro has been administered
to millions of patients in over 120 countries. Data from clinical
studies have published in scores in prestigious medical journals.
Setting standards:
Propofol-Lipuro sets standards that inspire imitators. The clinical benefits of MCT/LCT are superior to LCT or MCT emulsions.
To date, Propofol-Lipuro remains the only formulation proven to
reduce pain on injection.
Service continuity:
In line with our slogan Sharing Expertise, Propofol-Lipuro is
further proof of B. Brauns continued commitment to patients and
doctors, hospital and community.
There is only one Propofol-Lipuro. Go for the original.
Propofol-Lipuro 20 mg/ml
Injectable Drugs
Propofol-Lipuro 10 mg/ml
Propofol-Lipuro 20 mg/ml
% of Patients
% of Patients
60
12
50
10
40
30
6
37 %
20
10
0
Propofol-Lipuro
Propofol-LCT
days
% killed bacteria
15
90
p<0.05
p<0.05
80
10
70
60
0%
64 %
10
10.7%
14
76.3%
79.4%
79.9%
67.4%
day 0
day 2
day 0
day 2
50
40
Propofol-Lipuro
Propofol-LCT
0
MCT/LCT emulsion
LCT emulsion
d) Marsili I, Iovinelli G, et al. Parenteral nutrition in COPD patients: long vs. mediumchain triglycerides (MCT). Clinical Nutrition 1992; 11: 45, special supplement
e) Waitzberg DL, Bellinati-Pires R, et al. Effect of total parenteral nutrition with
different lipid emulsions on human monocyte and neutrophil funcions.
Nutrition 1997; 13: 128-132
MCT/LCT emulsion
LCT emulsion
Injectable Drugs
1984
Lipofundin MCT/LCT
First MCT/LCT emulsion
is developed
Literature on ...
Reduction of injection pain
Pediatric patients
1999
Propofol-Lipuro 10 mg/ml First propofol in MCT/LCT
emulsion is launched
Bachmann-Mennenga B, Ohlmer A, et al.
Incidence of pain after intravenous injection of
a medium-/long-chain triglyceride
emulsion of propofol. An observational study
in 1375 patients.
Arzneimittelforschung 2003; 53(9): 621-6
2001
Propofol-Lipuro 20 mg/ml
First Propofol 20 mg/ml in
MCT/LCT emulsion is
introduced
4.
1.
2.
3.
8.
9.
5.
38. Gelas P, Cotte L, et al. Effect of parenteral medium and long-chain triglycerides on lymphocytes
subpopulations and functions in patients with
acquired immunodeficiency syndrome:
a prospective study. JPEN 1998; 22: 67-71
2002
Propofol-Lipuro 10 mg/ml First propofol for induction and
maintenance of anesthesia in
children one month or older
6.
2008
Propofol-Lipuro 5 mg/ml
First Propofol 5 mg/ml in
MCT/LCT emulsion is
introduced
Auerswald K, Pfeiffer F, et al. Pain on injection
with propofol. Anasthesiol Intensivmed
Notfallmed Schmerzther 2005; 40(5): 259-66
7.
2012
Propofol-Lipuro is
marketed in > 120
countries